Literature DB >> 3572809

Different P2-purinergic receptor subtypes of endothelium and smooth muscle in canine blood vessels.

D A Houston, G Burnstock, P M Vanhoutte.   

Abstract

P2-Purinergic agonists can induce direct contractions in saphenous veins and endothelium-dependent relaxations in coronary arteries of the dog. For contractions, the rank order of agonist potency was alpha, beta-methylene-ATP much greater than ATP greater than ADP. For endothelium-dependent relaxation, the order was 2-methylthio-ATP greater than ADP greater than ATP much greater than alpha, beta-methylene-ATP (the latter causing no relaxation), suggesting two different subtypes of the P2-purinoceptors in these tissues. alpha, beta-Methylene-ATP could be used like an antagonist in the saphenous vein because it desensitizes receptors; exposure to it prevented contractions to ADP or ATP, but did not inhibit relaxations to them in the coronary artery. Reactive blue 2, from 2 X 10(-6) to 2 X 10(-5) M, behaved as a competitive antagonist of relaxations of the coronary artery induced by ADP and 2-methylthio-ATP; it did not inhibit contraction of the saphenous vein by alpha, beta-methylene-ATP. It antagonized slightly the endothelium-dependent relaxation of the coronary artery to acetylcholine, but not that to the calcium ionophore A23187. In contrast, methylene blue, a functional antagonist of endothelium-dependent relaxations, caused noncompetitive antagonism of relaxation to the same agonists. Thus, different subtypes of P2-purinoceptors on canine vascular smooth muscle and endothelium can be distinguished on the basis not only of the potencies of a series of agonists, but by two antagonists which discriminate between them.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572809

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  Ca(2+)-stores mobilization by diadenosine tetraphosphate, Ap4A, through a putative P2Y purinoceptor in adrenal chromaffin cells.

Authors:  E Castro; J Pintor; M T Miras-Portugal
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  The effects of purine compounds on the isolated aorta of the frog Rana temporaria.

Authors:  G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 3.  Platelets, endothelium and blood vessel wall.

Authors:  P M Vanhoutte
Journal:  Experientia       Date:  1988-02-15

4.  Effects of P1 and P2Y purinoceptor antagonists on endothelium-dependent and -independent relaxations of rat mesenteric artery to GTP and guanosine.

Authors:  P Vuorinen; X Wu; P Arvola; H Vapaatalo; I Pörsti
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Evidence for a nucleotide receptor on adrenal medullary endothelial cells linked to phospholipase C and phospholipase D.

Authors:  J R Purkiss; G F Wilkinson; M R Boarder
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

Review 6.  Pannexin 1 in the regulation of vascular tone.

Authors:  Marie Billaud; Joanna K Sandilos; Brant E Isakson
Journal:  Trends Cardiovasc Med       Date:  2012-07-28       Impact factor: 6.677

7.  The regulation of aortic endothelial cells by purines and pyrimidines involves co-existing P2y-purinoceptors and nucleotide receptors linked to phospholipase C.

Authors:  G F Wilkinson; J R Purkiss; M R Boarder
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

8.  Responses of the aorta of the garter snake (Thamnophis sirtalis parietalis) to purines.

Authors:  G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

9.  Vascular actions of purines in the foetal circulation of the human placenta.

Authors:  M A Read; A L Boura; W A Walters
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Increased flow-induced ATP release from isolated vascular endothelial cells but not smooth muscle cells.

Authors:  P Bodin; D Bailey; G Burnstock
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.